- China Overcapacity Worsening, EU Chamber Warns
- Investing in Good Karma – and Making a Profit
- UK Banks Must Disclose Top Pay: Review
- Black Friday to Avoid Red Ink; Greenback Gets the Blues
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
- Fed to Counsel Moviegoers on How to Use Credit Cards
- Where Do Pardoned Turkeys Go?
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- China announces plan to boost energy efficiency
- Malaysia plans 4 percent sales tax by 2011
- Australian tax office bills TPG for $629 million
- Neb. drops theft charges against auto executives
- Judge tells Reserve Primary fund to pay out assets
- Freedom Comm. discloses buyer for Arizona paper
- AIG cuts salaries to 3 top executives
- Correction: Credit Suisse-Colorado story
- Global Defense Technology & Systems closes IPO
Text Size 
NEW YORK - Cephalon Inc. will give Barr Pharmaceuticals Inc. a license to sell a generic version of the pain drug Fentora in 2018 as part of a patent lawsuit settlement, according to a Securities and Exchange Commission filing Thursday.
In the filing, Cephalon said it will give Barr a non-exclusive, royalty-free right to sell a generic version of Fentora in October of 2018. Cephalon said the patent is not set to expire until 2019.
Barr is now part of Israel-based Teva Pharmaceutical Industries.
The deal doesn't affect the status of the separate Fentora patent lawsuits with Watson Pharmaceuticals Inc. and its units.
If another generic version of Fentora reaches the U.S. market before October of 2018, Barr is allowed to launch its version.
Shares of Cephalon, which is headquartered in Frazer, Pa., fell $1.09 to close at $58.84.
Print
Email
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
- How can you get out of debt and back on the road to recovery? Follow these ten steps.
Data is a real-time snapshot *Data is delayed at least 15 minutes